ettx stock yahoo
A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. 2.7500 -0.07 (-2.48%)After hours: 7:44PM EDT. We initiated ATTACK, our single Phase 3 registration trial in April 2019. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). For more information, visit www.entasistx.com. © 2021 Verizon Media. Find the latest Entasis Therapeutics Holdings I (ETTX) stock discussion in Yahoo Finance's forum. View live ENTASIS THERAPEUTICS HLDGS INC chart to track its stock's price action. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%. The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Find Yahoo Finance-predefined, ready-to-use stock screeners to search for stocks by industry, index membership and more. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investment decisions. Interactive chart for Entasis Therapeutics Holdings I (ETTX) – analyse all of the data with a huge range of indicators. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. View the real-time ETTX price chart on Robinhood and decide if you want to buy or sell commission-free. Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. To help provide a sense of the short to long-term trend, included is an interactive Entasis Therapeutics stock chart which you can easily adjust to the time frame of your choosing (e.g. ATTACK is a global Phase 3 registration trial that is actively enrolling patients at sites in 17 countries including China. The new monthly stimulus checks for families: How do you get them, and when? Latest 10 SEC filings (by transaction date) for ETTX within the last 6 months : Amended Filing Footnote and/or Remark: As of 11:59pm ET March 14th, 2021. ETTX 2.92 0.12 (3.95%). Share your opinion and gain insight from other stock traders and investors. Many of these factors are beyond Entasis’ control. Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Entasis Therapeutics Ltd PRIVATE Updated Mar 16, 2021 9:07 PM. USAA CEO on the company's response to the coronavirus, Don't make this mistake with your new $1,400 stimulus check. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Currency in USD. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter … Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Entasis Therapeutics against related stocks people have also bought. Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com Investor Relations ContactJames SaliernoThe Ruth Group(646) 536-7035 / (646) 536-7028jsalierno@theruthgroup.com Media ContactAnnika ParrishThe Ruth Group(508) 280-6592aparrish@theruthgroup.com, WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. In depth view into ETTX (Entasis Therapeutics Holdings) stock including the latest price, news, dividend history, earnings information and financials. ETTX stock was acquired by a variety of institutional investors in the last quarter, including Pivotal bioVenture Partners Investment Advisor LLC, Renaissance Technologies LLC, Virtu Financial LLC, Squarepoint Ops LLC, Jaffetilchin Investment Partners LLC, and Janney Montgomery Scott LLC. If you want to know who really controls Entasis Therapeutics Holdings Inc. ( NASDAQ:ETTX ), then you'll have to look at... WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter baumannii infections, including carbapenem and multidrug resistant strains. All rights reserved. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Entasis Therapeutics Holdings Inc. Common Stock (ETTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. © 2021 Verizon Media. The Company’s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually.About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Find market predictions, ETTX financials and market news. At this time, the EAP is open to patients only in the U.S. About SUL-DURSUL-DUR is an intravenous, or IV, investigational drug that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor, or BLI, that we are developing for the treatment of infections caused by Acinetobacter baumannii, including carbapenem-resistant strains. ETTX Stock Summary. ETTX | Complete Entasis Therapeutics Holdings Ltd. stock news by MarketWatch. In the short term (2weeks), ETTX's stock price should outperform the market by 6.46%.During that period the price should oscillate between -10.77% and +17.63%. ETTX on Yahoo! Physicians seeking pre-approval access for patients with no alternative treatment options should submit their requests to Expandedaccess@entasistx.com. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. View Entasis Therapeutics Holdings Inc. ETTX investment & stock information. In this circumstance, Entasis Therapeutics can provide a requesting physician with pre-approval access to SUL-DUR for the treatment of the physician’s patient if specific conditions are met and there is adequate availability of drug supply. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. using the scroll bar or pinch and zoom on a touch screen). This stock, which remained volatile and traded within the range of $2.54 –$3.32 in the past one-month time frame, witnessed a sharp increase on Friday. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Post-Market 0.01 (0.34%) Entasis Forward-looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. View real-time stock prices and stock quotes for a full financial overview. Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. The following presents a detailed Entasis Therapeutics stock price history for your review. Finance; ETTX on TradingView; ETTX on StockCharts.com; ETFs Holding ETTX; Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis Therapeutics Awarded Contract from National Institutes of Health Stock analysis for Entasis Therapeutics Holdings Inc (ETTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2.7500 -0.07 (-2.48%)After hours: 7:44PM EDT. Actual results may differ materially from these forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. All quotes are in local exchange time. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery…See this and similar jobs on LinkedIn. The move came on solid volume too with far more shares changing hands than in a normal session. Yahoo | August 5, 2020. https://www.linkedin.com/jobs/view/director-of-gmp-quality-assurance-at-entasis-therapeutics-2402472779?refId=4226f5ae-af02-4792-84a1-b32a76ac252f&trackingId=hwHt%2F%2FjN%2FK6VLFFBJ%2BZvFw%3D%3D&position=5&pageNum=0&trk=public_jobs_job-result-card_result-card_full-click. Growth stocks can be more volatile than other types of stocks. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. All rights reserved. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. “We are excited to have in place an EAP for patients who are not eligible to participate in our study and who are suffering from a serious and life-threatening infection caused by drug resistant Acinetobacter.” In cooperation with the FDA, expanded access, also referred to as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. “The ability to provide access to patients in need is consistent with the Entasis mission,” said David Altarac, M.D., Chief Medical Officer. While the F1 consensus estimate and revision is a key driver of stock prices, the Q1 consensus is an important item as well, especially over the short-term, and particularly as a stock … Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Yahoo | July 13, 2020. Stock quote and company snapshot for ENTASIS THERAPEUTICS HOLDINGS INC (ETTX), including profile, stock chart, recent news and events, analyst opinions, and research reports. Posted 4 weeks ago. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access … Currency in USD, Trade prices are not sourced from all markets. For more information, visit www.entasistx.com.Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.comInvestor Relations Contact James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.comMedia Contact Annika Parrish The Ruth Group (720) 412-9042 aparrish@theruthgroup.com, Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGM - NasdaqGM Real Time Price. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4% finance.yahoo.com - July 13 at 12:52 PM: Entasis Therapeutics nabs NIH contract for $3M seekingalpha.com - July 6 at 1:09 PM: Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference finance.yahoo.com - June 18 … It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Value stocks can continue to be undervalued by the market for long periods of time. Create your own screens with over 150 different screening criteria.